These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 10942052)

  • 1. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.
    Hamilton A; Piccart M
    Ann Oncol; 2000 Jun; 11(6):647-63. PubMed ID: 10942052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 status.
    Köstler WJ; Brodowicz T; Hudelist G; Rudas M; Horvat R; Steger GG; Singer CF; Attems J; Rabitsch W; Fakhrai N; Elandt K; Wiltschke C; Hejna M; Zielinski CC
    J Cancer Res Clin Oncol; 2005 Jul; 131(7):420-8. PubMed ID: 15864644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
    Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923.
    Hamilton A; Larsimont D; Paridaens R; Drijkoningen M; van de Vijver M; Bruning P; Hanby A; Houston S; Treilleux I; Guastalla JP; Van Vreckem A; Sylvester R; Piccart M
    Clin Breast Cancer; 2000 Oct; 1(3):233-40; discussion 241-2. PubMed ID: 11899648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
    Malamou-Mitsi V; Gogas H; Dafni U; Bourli A; Fillipidis T; Sotiropoulou M; Vlachodimitropoulos D; Papadopoulos S; Tzaida O; Kafiri G; Kyriakou V; Markaki S; Papaspyrou I; Karagianni E; Pavlakis K; Toliou T; Scopa C; Papakostas P; Bafaloukos D; Christodoulou C; Fountzilas G
    Ann Oncol; 2006 Oct; 17(10):1504-11. PubMed ID: 16968874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of HER2 in breast cancer.
    Piccart M; Lohrisch C; Di Leo A; Larsimont D
    Oncology; 2001; 61 Suppl 2():73-82. PubMed ID: 11694791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy.
    Mottolese M; Benevolo M; Del Monte G; Buglioni S; Papaldo P; Nisticò C; Di Filippo F; Vasselli S; Vici P; Botti C
    J Cancer Res Clin Oncol; 2000 Dec; 126(12):722-9. PubMed ID: 11153146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
    Kim R; Tanabe K; Emi M; Uchida Y; Toge T
    Cancer; 2005 May; 103(10):2199-207. PubMed ID: 15830342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Her-2/neu and breast cancer.
    Kaptain S; Tan LK; Chen B
    Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status.
    Brodowicz T; Kandioler D; Tomek S; Ludwig C; Rudas M; Kunstfeld R; Koestler W; Hejna M; Budinsky A; Wiltschke C; Zielinski CC
    Br J Cancer; 2001 Nov; 85(11):1764-70. PubMed ID: 11742500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment.
    Farczádi E; Kaszás I; Baki M; Szende B
    Neoplasma; 2002; 49(2):101-3. PubMed ID: 12088100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?
    Piccart MJ; Di Leo A; Hamilton A
    Eur J Cancer; 2000 Sep; 36(14):1755-61. PubMed ID: 10974622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From HER2 to herceptin.
    Mokbel K; Hassanally D
    Curr Med Res Opin; 2001; 17(1):51-9. PubMed ID: 11464447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer in the clinic: treatments past, treatments future.
    Sledge GW
    J Mammary Gland Biol Neoplasia; 2001 Oct; 6(4):487-95. PubMed ID: 12013537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.
    Kai K; Nishimura R; Arima N; Miyayama H; Iwase H
    Int J Clin Oncol; 2006 Dec; 11(6):426-33. PubMed ID: 17180510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy in breast cancer: the HER-2/neu gene and protein.
    Ross JS; Fletcher JA; Bloom KJ; Linette GP; Stec J; Symmans WF; Pusztai L; Hortobagyi GN
    Mol Cell Proteomics; 2004 Apr; 3(4):379-98. PubMed ID: 14762215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.